TNF and inflammatory bowel disease: Several studies have demonstrated that patients with inflammatory bowel disease (IBD) undergoing anti-TNF therapy; combination therapy of anti-TNF and thiopurines; or tofacitinib exhibit a significantly impaired humoral immune response following the second SARS-CoV-2 vaccination [13,14,20,21].